Merck & Co., Inc. (MRK) — Available-Data Snapshot
Updated Sep 3, 2026 · available-data snapshot · descriptive, not a DCF, not advice
We don't publish a discounted-cash-flow fair value for Merck & Co., Inc. (MRK) because the free data sources we rely on don't expose the multi-year financials a DCF needs — common for small or thinly-covered listings. Rather than invent numbers, this page shows an honest snapshot of what the public data does support: the current price and size, any relative valuation multiples that exist, a book-value view, and a price-based read. Treat it as a descriptive starting point, not a valuation and not investment advice.
On the numbers we do have, MRK trades at a recent price of $151.64, a market capitalisation of about $374,121,889,792, sitting 93% of the way up its 52-week range ($77.58–$156.92), on the NYSE.
The standard alternative to a DCF is relative valuation — comparing MRK's trading multiples against its direct industry peers. Here that gives P/E of 122.3× (richer than the peer median of 37.7×); Fwd P/E of 15.9× (in line with the peer median of 16.1×); P/B of 8.9× (richer than the peer median of 7.0×); P/S of 5.6× (cheaper than the peer median of 6.8×); EV/EBITDA of 14.6× (cheaper than the peer median of 17.1×); Dividend yield of 2.2% (richer than the peer median of 2.6%). A cheaper multiple than peers can flag a discount or a market that expects weaker growth; it is a comparison, not a recommendation.
The asset, or book-value, lens is the classic tool for asset-heavy businesses and financials. MRK shows a price-to-book (P/B) of 8.93 and book value of $16.99 per share. Price-to-book compares the market price to the accounting net-asset value per share; below 1.0 can mean a discount to net assets or that the market is pricing in trouble — descriptive either way, never a buy signal on its own.
Finally, a price-based read — explicitly not a valuation. MRK is in an up-trend (price above both its 50- and 200-day averages), trading -3.4% from its 52-week high. Over the past year the stock is +78.3%. Moving-average trend and 52-week position describe where the stock has traded; they say nothing about what it is worth.
Relative valuation — MRK vs peers
| Multiple | MRK | Peer median | |
|---|---|---|---|
| P/E | 122.3× | 37.7× | richer than |
| Fwd P/E | 15.9× | 16.1× | in line with |
| P/B | 8.9× | 7.0× | richer than |
| P/S | 5.6× | 6.8× | cheaper than |
| EV/EBITDA | 14.6× | 17.1× | cheaper than |
| Dividend yield | 2.2% | 2.6% | richer than |
Direct industry peers.
Asset / book-value view
Price-to-book compares the market price to the accounting net-asset value per share. Most useful for asset-heavy businesses, banks and insurers.
Price-based snapshot
Price-based, not a valuation. Moving-average trend and 52-week position describe where the stock has traded — they say nothing about fair value.
Compare MRK with its peers
Companies people research alongside MRK
Explore more
Most undervalued stocks (per our valuation) · All valued stocks · Interactive MRK viewA descriptive, available-data snapshot and relative comparison — NOT a DCF, NOT a price target, and NOT investment advice. TickerWorth is an educational tool, not a licensed investment adviser. Figures are estimates derived from public market data and can be wrong, stale or incomplete.